Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2020-04-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Huabang Life Health Co., Ltd. regarding the release of pledge on shares held by the actual controller, Mr. Zhang Songshan. It details the number of shares released from pledge, cumulative pledged shares, and reassures investors about the risk and control implications. The document is short (1602 characters) and focuses on share pledge status and related disclosures. It does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it is a compliance disclosure about share pledge changes and risk, not a financial report or capital raising update.
2020-04-28 Chinese
第七届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 11th meeting of the 7th Supervisory Board of Huabang Life Health Co., Ltd. It includes approvals of the company's 2020 first quarter report, audit opinions, and multiple resolutions related to the spin-off and listing of a subsidiary (Shandong Kaisheng New Materials Co., Ltd.) on the Shenzhen Stock Exchange's ChiNext board. The document discusses compliance with relevant laws, financial performance, independence, and governance of the subsidiary, and states that these resolutions will be submitted to the shareholders' meeting for approval. The document is not the actual quarterly report but a formal announcement of supervisory board decisions and approvals related to the report and corporate actions. It contains no full financial statements or detailed financial analysis itself but references the report published elsewhere. The primary purpose is to disclose board-level decisions and approvals, which fits the category of Board/Management Information (MANG).
2020-04-28 Chinese
第七届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 15th meeting of the 7th Board of Directors of Huabang Life Health Co., Ltd. It includes multiple agenda items related to the proposed spin-off and listing of a subsidiary, Shandong Kaisheng New Materials Co., Ltd., on the Shenzhen Stock Exchange's ChiNext board. The document discusses the background, purpose, legal compliance, financial data, and governance aspects of the spin-off and listing plan. It also mentions the voting results of the board meeting and the need to submit these proposals to the shareholders' meeting for approval. The content is focused on board decisions and management-level approvals rather than being a full financial report, earnings release, or investor presentation. It is not a simple announcement of a report publication but a substantive board meeting resolution document. Therefore, the filing type best fitting this document is Board/Management Information (MANG).
2020-04-28 Chinese
关于本次上市公司分拆子公司上市董事会决议日前股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a public announcement by Huabang Health Co., Ltd. regarding the stock price volatility before the board resolution on the spin-off and listing of its subsidiary. It references regulatory standards from the China Securities Regulatory Commission and provides detailed stock price data and analysis to demonstrate compliance with disclosure rules. The document is short (1297 characters) and focuses on regulatory compliance and stock price movement analysis related to a corporate action (subsidiary spin-off). It does not contain financial statements, audit opinions, or detailed financial results. It is not a full report but a regulatory announcement explaining the stock price behavior in relation to a specific event. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-04-28 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 First Quarter Report" of 华邦生命健康股份有限公司 (Huabang Life Health Co., Ltd.). It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, and notes on financial performance for the first quarter of 2020. The presence of comprehensive financial statements and analysis for a quarterly period clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese
关于分拆所属子公司山东凯盛新材料股份有限公司至创业板上市的预案
Capital/Financing Update Classification · 95% confidence The document is a detailed plan (预案) for the spin-off and listing of a subsidiary company (山东凯盛新材料股份有限公司) on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive information about the background, purpose, legal compliance, financial data, risk factors, and procedural steps related to the spin-off and IPO. The document is not a financial report like an annual or interim report, nor is it a simple announcement or voting result. It is a comprehensive proposal document related to a capital restructuring and listing event. This fits the category of Capital/Financing Update (CAP), as it provides detailed information about a financing activity (spin-off and IPO) and capital structure changes.
2020-04-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.